Gyre Therapeutics, Inc. (GYRE)の価格はいくらですか

Gyre Therapeutics, Inc. (GYRE)の価格は$6.61です

Gyre Therapeutics, Inc. (GYRE)の時価総額は何ですか

Gyre Therapeutics, Inc. (GYRE)の時価総額は$736.94Mです

Gyre Therapeutics, Inc. (GYRE) の利益

Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.

年	利益	変化
提供された日付のデータは十分ではありません。

年

利益

変化

提供された日付のデータは十分ではありません。

企業	利益	利益の差	国
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
CSL Limited CSL.AX	$-4.02B	-	AU
Moderna, Inc. MRNA.US	$-3.09B	-	US
Lonza Group AG LONN.SW	-	-	CH

企業

利益

利益の差

国